"The proposed mechanism of action of rocatinlimab, as a first-in-class T-cell rebalancing therapy, is supported by specific reduction of OX40R-positive T cells while maintaining conventional T ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...

CD8-positive T cells are a critical subpopulation of MHC class I-restricted T cell and are mediators of adaptive immunity. They include cytotoxic T cells, which are important for killing cancerous ...